H. Lundbeck A Logo

H. Lundbeck A

Develops and commercializes innovative therapeutics for brain diseases globally.

HLUN | CO

Overview

Corporate Details

ISIN(s):
DK0061804697 (+5 more)
LEI:
5493006R4KC2OI5D3470
Country:
Denmark
Address:
Ottiliavej 9, 2500 Valby
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

H. Lundbeck A/S is a global pharmaceutical company dedicated exclusively to developing and commercializing innovative treatments for brain diseases. The company's core focus is on neuroscience, engaging in the full value chain of research, development, manufacturing, and sales of therapeutics for psychiatric and neurological disorders. Its portfolio addresses a variety of conditions, including depression, migraine, and rare epilepsies. With a mission to advance brain health, Lundbeck markets its specialized products in numerous countries worldwide, managing operations from initial research to patient delivery.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-12-01 08:39
M&A Activity
ANNOUNCEMENT FOR THE PURPOSES OF ARTICLE 17 MARKET ABUSE REGULATION (EU) NO. 59…
English 85.6 KB
2025-11-14 14:51
Regulatory Filings
English 96.8 KB
2025-11-14 12:45
M&A Activity
English 25.3 KB
2025-11-14 12:45
Regulatory Filings
English 96.8 KB
2025-11-11 15:22
Regulatory Filings
English 116.4 KB
2025-11-11 15:22
Earnings Release
English 24.6 KB
2025-09-20 08:00
Regulatory Filings
English 146.2 KB
2025-09-20 08:00
Legal Proceedings Report
English 30.0 KB
2025-08-13 18:41
Interim / Quarterly Report
English 1.0 MB
2025-08-13 18:41
Earnings Release
English 32.1 KB
2025-08-13 18:35
Earnings Release
English 24.2 KB
2025-08-13 18:35
Earnings Release
English 129.5 KB
2025-02-21 13:27
Director's Dealing
English 124.1 KB
2025-02-21 13:27
Director's Dealing
English 29.9 KB
2025-02-05 16:40
Director's Dealing
English 134.1 KB

Automate Your Workflow. Get a real-time feed of all H. Lundbeck A filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for H. Lundbeck A

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for H. Lundbeck A via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

S2Medical AB Logo
Develops advanced wound healing and infection control solutions for burns and chronic wounds.
Sweden
S2M
SAB Biotherapeutics, Inc. Logo
Develops human polyclonal antibodies for autoimmune disorders and infectious diseases.
United States of America
SABS
Sagimet Biosciences Inc. Logo
Clinical-stage biopharma developing FASN inhibitors for MASH, acne, and cancer.
United States of America
SGMT
Sam-A Pharm. Co. Ltd Logo
South Korea
009300
SAMIL PHARMACEUTICAL CO.,LTD Logo
Develops & manufactures drugs for eye & liver diseases, with a broad portfolio & CDMO services.
South Korea
000520
SAMJIN PHARMACEUTICAL CO.,LTD Logo
Researches & develops drugs for cardiovascular, respiratory, and gastrointestinal disorders.
South Korea
005500
SAMSUNG BIOLOGICS CO.,LTD. Logo
A CDMO providing end-to-end development and manufacturing services for the biopharma industry.
South Korea
207940
Sana Biotechnology, Inc. Logo
Engineering cells as medicine to repair genes and treat cancer, diabetes, and autoimmune disorders.
United States of America
SANA

Talk to a Data Expert

Have a question? We'll get back to you promptly.